A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma
Ran Xue, Miaoyan Wei, Jiajia Yuan, Zhihua Li, Yuhong Zhou, Zeyun Xue, Yiwen Wu, Hongxia Han, Jun Zhou, Xianjun Yu, Lin Shen · 2025
Read A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma by Ran Xue, Miaoyan Wei, Jiajia Yuan, Zhihua Li, Yuhong Zhou, Zeyun Xue, Yiwen Wu, Hongxia Han, Jun Zhou, Xianjun Yu, Lin Shen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12718313.txt.
Description
Ran Xue and co-authors test a two-in-one immune drug added to standard chemotherapy for advanced pancreatic cancer. Their 2025 trial report covers a fusion protein that blocks the PD-L1 checkpoint while also trapping TGF-beta, a signal tumors use to hide. Fifty-six patients with advanced pancreatic ductal adenocarcinoma received it with the standard two-drug chemotherapy backbone.
About a third of patients saw their tumors shrink, and typical survival reached roughly ten months in a disease where gains are hard won. Serious treatment side effects hit just under half the patients, led by lowered white cell counts. Patients whose tumors carried more PD-L1 responded markedly better, with survival nearly doubled in that small subgroup. Marker changes during treatment also tracked outcomes. The authors call the combination promising and manageable, and they sketch which patients benefit most.
Catalog record
| CREATOR | Ran Xue, Miaoyan Wei, Jiajia Yuan, Zhihua Li, Yuhong Zhou, Zeyun Xue, Yiwen Wu, Hongxia Han, Jun Zhou, Xianjun Yu, Lin Shen |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |